featured
Efficacy and Safety of Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease Treated With Mycophenolate
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Mycophenolate: A Subgroup Analysis of the SENSCIS Trial
Lancet Respir Med 2021 Jan 01;9(1)96-106, KB Highland, O Distler, M Kuwana, Y Allanore, S Assassi, A Azuma, A Bourdin, CP Denton, JHW Distler, AM Hoffmann-Vold, D Khanna, MD Mayes, G Raghu, MC Vonk, M Gahlemann, E Clerisme-Beaty, M Girard, S Stowasser, D Zoz, TM Maher,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.